Introduction
In this video interview with Video Journal of Biomedicine, David Thompson, Syneos Health, provides his thoughts on the role of real-world evidence (RWE) in healthcare decision making. Reflecting on recent examples where RWE has been used by regulatory bodies in drug approvals, David also discusses the importance of well-designed RWE studies to ensure it can be considered by regulatory bodies and how new technologies, such as virtual research, are being used to generate RWE.
And so what we always advocate is that you engage with the health system stakeholders first. It's not just regulatory when you're talking about real-world evidence. It's payers at the very top of the list, health technology assessment agencies as well, patient organizations, and clinicians. So you have five different health system stakeholders that are going to have different evidentiary needs, and it's important to talk to them upfront such that when you develop your body of real-world evidence, you have a good sense that it's going to meet their decision-making needs.
- David Thompson
About the Author
David Thompson, PhD is Senior Vice President, Real World Evidence Advisory at Syneos Health. David is a health economist with 30 years of experience in the health economics arena, including work in economic modeling, retrospective database analysis, trial-based economic evaluations, and patient-reported outcomes. David is the Editor-in-Chief of Value & Outcomes Spotlight, the journal of the Professional Society for Health Economics and Outcomes Research (ISPOR), and a steering committee member of the Clinical Trials Transformation Initiative (CTTI), a multistakeholder initiative of Duke University and the FDA, and a member of the CTTI initiative in real world evidence. David can be reached at [email protected]
